Öz
Amaç
İnterlökin-32’nin (IL-32) vasküler düz kas hücresi aktivasyonunda, aterosklerozda ve endotelyal enflamasyonda rolü vardır. Bu çalışmada damar tutulumu olan Behçet hastalığında (BH) serum IL-32 düzeylerinin artıp artmadığını, ayrıca IL-32 düzeyleri ile hastalık aktivitesi arasındaki ilişkiyi inceledik.
Yöntem
Bu kesitsel çalışmada 42 BD hastası ve 38 sağlıklı birey yaş ve cinsiyete göre eşleştirildi. Behçet hastalarını damar tutulumu olup olmamasına göre iki gruba ayırdık. Hastaların demografik verileri, hastalık süreleri, hastalık aktiviteleri ve tedavileri kaydedildi. Çalışılan örneklerde tümör nekroz faktörü (TNF)-alfa, IL-6, IL-17 ve IL-32’nin serum konsantrasyonlarını belirlemek için Enzime Bağlı İmmünosorbent testi tekniği kullanıldı. Behçet Sendromu Aktivite ölçeği (BSAS) ve Behçet Hastalığı Güncel Aktivite formu (BDCAF) kullanılarak hastalık aktivitesinin değerlendirilmesi yapıldı.
Bulgular
Damar tutulumu olan ve olmayan BH’nin klinik özellikleri karşılaştırıldığında anlamlı bir fark saptanmadı. Vasküler tutulumun varlığı, TNF-alfa ve IL-32’nin serum seviyelerini etkiledi. Damar tutulumu olan BH’de serum IL-32 ve TNF-alfa düzeyleri sağlıklı kontrollere göre anlamlı derecede yüksekti (sırasıyla p=0,003; p=0,001). Damar tutulumu olan Behçet hastalarında, damar tutulumu olmayan BH’ye göre serum IL-32 düzeyleri istatistiksel olarak farklıydı (sırasıyla p=0,008). Serum IL-32 seviyeleri, dönüştürülmüş BDCAF ve BSAS aktivite ölçekleri ile hiçbir ilişki göstermedi.
Sonuç
Çalışma sonuçlarımız Behçet hastalarında serum IL-32 düzeylerinin yükseldiğini ve bunun vasküler tutulumla ilişkili olabileceğini gösterdi.
Anahtar Kelimeler: Behçet hastalığı, damar tutulumu, interlökin-32
Kaynakça
Hatemi G, Yazici Y, Yazici H. Behçet’s syndrome. Rheum Dis Clin North Am. 2013;39:245-61.
Ishigatsubo Y. Statement draft for clinical guidelines of vasculo- Behçet’s disease. [Internet]. 2014 [cited 2018 Jun. 6] Available from:http://www.nanbyou.or.jp/upload_files/Bechet2014_4.pdf (in Japanese).
Seyahi E, Yurdakul S. Behçet’s syndrome and thrombosis. Mediterr J Hematol Infect Dis. 2011;3:e2011026.
Ferrão C, Almeida I, Marinho A, Vasconcelos C, Correia JA. A nossa regra de ouro na doença de Behçet: tratar a manifestação clínica. Arq Med. 2015;29:75-9.
Dahl CA, Schall RP, He HL, Cairns JS. Identification of a novel gene expressed in activated natural killer cells and T cells. J Immunol. 1992;148:597-603.
Netea MG, Lewis EC, Azam T, et al. Interleukin-32 induces the differentiation of monocytes into macrophage-like cells. Proc Natl Acad Sci U S A. 2008;105:3515-20.
Kang JW, Choi SC, Cho MC, et al. A proinflammatory cytokine interleukin-32beta promotes the production of an anti-inflammatory cytokine interleukin-10. Immunology. 2009;128(1 Suppl):e532-40.
Khawar B, Abbasi MH, Sheikh N. A panoramic spectrum of complex interplay between the immune system and IL-32 during pathogenesis of various systemic infections and inflammation. Eur J Med Res 2015;20:7.
Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity. 2005;22:131-42.
Netea MG, Azam T, Ferwerda G, et al. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci U S A. 2005;102:16309-14.
Nold-Petry CA, Nold MF, Zepp JA, Kim SH, Voelkel NF, Dinarello CA. IL-32-dependent effects of IL-1beta on endothelial cell functions. Proc Natl Acad Sci U S A. 2009;106:3883-8.
Heinhuis B, Koenders MI, van den Berg WB, Netea MG, Dinarello CA, Joosten LA. Interleukin 32 (IL-32) contains a typical α-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1. J Biol Chem. 2012;287:5733-43.
Ciccia F, Alessandro R, Rizzo A, et al. Expression of interleukin-32 in the inflamed arteries of patients with giant cell arteritis. Arthritis Rheum. 2011;63:2097-104.
Yang Z, Shi L, Xue Y, et al. Interleukin-32 increases in coronary arteries and plasma from patients with coronary artery disease. Clin Chim Acta. 2019;497:104-9.
de Vargas RM, da Cruz MLN, Giarllarielli MPH, et al. Vascular involvement in Behçet’s disease: the immunopathological process. J Vasc Bras. 2021;20:e20200170.
Ha YJ, Park JS, Kang MI, Lee SK, Park YB, Lee SW. Increased serum interleukin-32 levels in patients with Behçet’s disease. Int J Rheum Dis. 2018;21:2167-74.
Choi YS, Kim S, Oh YS, Cho S, Hoon Kim S. Elevated serum interleukin-32 levels in patients with endometriosis: a cross-sectional study. Am J Reprod Immunol. 2019;82:e13149.
International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD). The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28:338-47.
Fei Y, Li X, Lin S, et al. Major vascular involvement in Behçet’s disease: a retrospective study of 796 patients. Clin Rheumatol. 2013;32:845-52.
Hatemi G, Merkel PA, Hamuryudan V, et al. Outcome measures used in clinical trials for Behçet syndrome: a systematic review. J Rheumatol. 2014;41:599-612.
Lawton G, Bhakta BB, Chamberlain MA, Tennant A. The Behcet’s disease activity index. Rheumatology (Oxford). 2004;43:73-8.
Son DJ, Jung YY, Seo YS, et al. Interleukin-32α inhibits endothelial inflammation, vascular smooth muscle cell activation, and atherosclerosis by upregulating timp3 and reck through suppressing microRNA-205 biogenesis. Theranostics. 2017;7:2186-203.
Kobayashi H, Yazlovitskaya EM, Lin PC. Interleukin-32 positively regulates radiation-induced vascular inflammation. Int J Radiat Oncol Biol Phys. 2009;74:1573-9.
Bengts S, Shamoun L, Kunath A, et al. Altered IL-32 signaling in abdominal aortic aneurysm. J Vasc Res. 2020;57:236-44.
Ibrahim SE, Elshishtawy HF, HelmySamy A, Galal ZA. Role of vascular endothelial growth factor and monocyte chemoattractant protein-1 in Behçet’s disease. Indian J Rheumatol. 2011;6:168-72.
Bassyouni IH, Sharaf M, Wali IE, Mansour HM. Clinical significance of angiopoietin-1 in Behcet’s disease patients with vascular involvement. Heart Vessels. 2016;31:918-24.
Kanazawa H. VEGF, angiopoietin-1 and -2 in bronchial asthma: new molecular targets in airway angiogenesis and microvascular remodeling. Recent Pat Inflamm Allergy Drug Discov 2007;1:1-8.
Zhao WB, Wang QL, Xu YT, Xu SF, Qiu Y, Zhu F. Overexpression of interleukin-32α promotes invasion by modulating VEGF in hepatocellular carcinoma. Oncol Rep. 2018;39:1155-62.
Li W, Liu Y, Mukhtar MM, et al. Activation of interleukin-32 pro-inflammatory pathway in response to influenza A virus infection. PloS One. 2008;3:e1985.
Kwon JW, Chang HS, Heo JS, et al. Characteristics of asthmatics with detectable IL-32γ in induced sputum. Respir Med. 2017;129:85-90.
Damen MSMA, Schraa K, Tweehuysen L, et al. Genetic variant in IL-32 is associated with the ex vivo cytokine production of anti-TNF treated PBMCs from rheumatoid arthritis patients. Sci Rep. 2018;8:14050.
Hong J, Bae S, Kang Y, et al. Suppressing IL-32 in monocytes impairs the induction of the proinflammatory cytokines TNFalpha and IL-1beta. Cytokine. 2010;49:171-6.
Fadaei R, Bagheri N, Heidarian E, et al. Serum levels of IL-32 in patients with type 2 diabetes mellitus and its relationship with TNF-a and IL-6. Cytokine. 2020;125:154832.
Moon YM, Yoon BY, Her YM, et al. IL-32 and IL-17 interact and have the potential to aggravate osteoclastogenesis in rheumatoid arthritis. Arthritis Res Ther. 2012;14:R246.
Mohammad-Rezaei M, Ahmadi R, Rafiei A, et al. Serum levels of IL-32 in patients with coronary artery disease and its relationship with the serum levels of IL-6 and TNF-a. Mol Biol Rep. 2021;48:4263-71.
Gui M, Zhang H, Zhong K, Li Y, Sun J, Wang L. Clinical significance of interleukin-32 expression in patients with rheumatoid arthritis. Asian Pac J Allergy Immunol. 2013;31:73-8.
Wang H, Wang K, Wang C, Xu F, Qiu W, Hu X. Increased plasma interleukin-32 expression in patients with neuromyelitis optica. J Clin Immunol. 2013;33:666-70.
Kaymaz S, Yilmaz H, Ufuk F, et al. Ultrasonographic measurement of the vascular wall thickness and intima-media thickness in patients with Behçet’s disease with symptoms or signs of vascular involvement: a cross-sectional study. Arch Rheumatol. 2021;14;36:258-66.
Buzatu C, Duffield S, Chadwick L, Moots RJ. THU0554 the clinical utility of two vasculitis activity scores (BVAS and BDCAF) in Behçet’s Syndrome: a prospective cohort study. Ann Rheum Dis. 2019;78:567.
